Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucidinostat plus capecitabine in metastatic TNBC
NCT05390476Phase 2Unknown
- Start
- Aug 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in triple-negative breast cancer (TNBC). Status: unknown.
02
Drugs
tucidinostat
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05390476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05390476.